Colleen Moretti


Sabizabulin Appears Safe, Effective in Metastatic Castration Resistant Prostate Cancer

September 19th 2021

Sabizabulin was well tolerated and associated with significant and durable objective tumor responses in patients with metastatic castration resistant prostate cancer.

Yoga Possesses Potential to Improve QoL, Immune Responses, and Inflammation in Prostate Cancer

September 13th 2021

Improvements in quality of life, antitumor immune responses, and inflammation could be resulting benefits of the incorporation of regular yoga practice in the lives of men with prostate cancer who are undergoing prostatectomy.

Systemic Review Underscores Need for Smoking Status Data on Genitourinary Cancer Trials

September 13th 2021

Smoking status is not often reported on genitourinary cancer clinical trials, which limits understanding of how smoking impacts the treatment, survival, and quality of life of this patient population.

Axi-Cel Induces Superior Responses, Survival in Relapsed/Refractory Follicular Lymphoma

June 12th 2021

Compared to currently available therapies, treatment with axicabtagene ciloleucel induced substantial objective response rate, progression-free survival, time to next treatment and overall survival improvements in patients with relapsed/refractory follicular lymphoma.

Selpercatinib Effective in RET Fusion–Positive NSCLC, Irrespective of Prior Therapies

June 5th 2021

Treatment with selpercatinib demonstrated consistent efficacy in patients with RET fusion-positive non-small cell lung cancer, regardless of prior treatments.

Aumolertinib Prolongs Survival, Duration of Response in NSCLC

June 5th 2021

Treatment with aumolertinib was associated with prolonged survival and duration of response in patients with non–small cell lung cancer.

Pralsetinib Is Tolerable, Durable in RET Fusion-Positive NSCLC

June 4th 2021

Updated findings from the ARROW trial demonstrated that pralsetinib could benefit those with RET fusion–positive non–small cell lung cancer and is a well-tolerated agent in the patient population.

Nivolumab/Cabozantinib Combo Improves Quality of Life in Advanced RCC

February 12th 2021

February 12, 2021 - Patients with advanced renal cell carcinoma reported improved health-related quality of life when treated with nivolumab plus cabozantinib compared with sunitinib

Immuno-Oncology Therapies Could Be More Beneficiary for Small Cell Lung Cancer

January 28th 2021

January 28, 2021 - Immuno-oncology therapies provided significant potential health gains for both patients and the population, although age should be taken into account to improve accuracy and avoid bias.

Nivolumab Improves Quality of Life in Patients with Esophageal/Gastroesophageal Cancer

January 15th 2021

January 15, 2021 - Patients with esophageal/gastroesophageal cancer treated with nivolumab had improved esophageal-specific and general quality of life, although trends were similar in those treated with placebo.

Pregnancy May Be Difficult for Breast Cancer Survivors, But Often Produces Healthy Babies with No Impact on Long-Term Survival

December 10th 2020

December 10, 2020 - Women who survive breast cancer may have more difficulty in becoming pregnant when compared to the general population, and have a risk of preterm labor, but most deliver healthy babies and experience no detrimental effects on their long-term survival.